Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Namaste Technologies CEO Sean Dollinger fires back after Andrew Left calls the stock a 'joke'

Shares of the cannabis e-commerce platform immediately fell on the news
Namaste Technologies Inc CEO Sean Dollinger
The co-founder invited the short-seller to spend a weekend following him around to see it's no joke

Namaste Technologies Inc (CVE:N, OTCQB:NXTTF) co-founder and CEO Sean Dollinger fired right back at Andrew Left's Citron Research after the notorious short-seller called the cannabis e-commerce platform's shares a "joke" in a report Friday generated by his Citron Research.

“Tell [Left] he can come and hang out with me on the weekend, travel around the world," Dollinger told Proactive Investors' Christine Corrado in an exclusive phone interview. "Tell him it’s a formal invite from me. Have him videotape everything we’re doing on site, we’ll prove to him that he’s the joke.”

Vancouver-based Namaste recently revealed plans to uplist to the Nasdaq in the hopes of reaching a larger audience of retail and institutional investors, but Left was deeply skeptical about the move.

"Some cannabis stocks are overvalued, and some are total jokes," tweeted Left, putting Namaste Technologies in the "joke" category. He advised investors to get out quick, saying it will not be able to list.

Citron forecast the stock to fall more than 80% from its current price to US$0.25.

Shares of Namaste in Canada closed on Friday 7.8% down at C$2.84, having dropped during the session as much as 17.2% to the day's low of C$2.55 on the news.

US-listed shares on the OTC markets  fell 8.4% to finish at US$2.16, likewise tumbling almost 17.4% to a session low of US$1.95.

"This is a C$1bn company that does not grow cannabis, rather they sell vape pens and have a website that did a paltry C$46k in revenue last quarter as they lost C$9mln," wrote Citron Research analysts. "This is the type of euphoria, hype and promotion that the SEC has been warning investors about." 

Citron said the last few weeks have been strong for Cannabis stocks that trade in the US and "investors have gone feverishly wild" in creating bubble-like valuations.

"While you can’t blame real companies like Aphria and Canntrust on hoping to join the party through a NASDAQ listing, you have to expect some party crashers to show up," the analysts wrote.

Not just blowing smoke

A team of  MIT engineers and Wall Street analysts called Trefis, however, put a $7 price target on Namaste Technologies saying the company aims to become the “Amazon of Cannabis” in the coming years. 

"We currently have a price estimate of $7 per share for Namaste Technologies, which is higher than its market price," wrote the Trefis Team in Forbes on Friday. "The company’s websites have over 600,000 monthly visits with a database of approximately 1.5 million users."

Trefis analysts wrote the company has "a strong presence" in the UK, Canada, and Germany and holds "a large chunk" of the online cannabis markets in Europe and Australia.

"With the growing demand for medical cannabis products, the company is catering to the emerging markets such as Brazil, Mexico, and Chile through a number of new supply channels," the analysts added.

READ: Namaste Technologies builds UK medical cannabis footprint with acquisition of pharma distributor AF Trading

Left's criticism comes at a time when Namaste Technologies has been particularly busy making smart acquisitions and forging tie-ups to grow its global footprint. The company announced Thursday that its wholly owned subsidiary, Namaste Bahamas, will acquire UK-based AF Trading Ltd, which operates as Access Fulfillment, for C$5mln.

No capital-raise will be required as Access Fulfillment will receive half the payment in cash and the rest in Namaste stock. In exchange, Access Fulfillment will operate as Namaste's distribution center for CBD, or cannabidiol, a compound found in the hemp or cannabis plant that helps with sleep and anxiety, and cannabis products in the United Kingdom.

Access Fulfillment operates a 30,000 square-foot distribution facility in the UK and holds a license to distribute pharmaceutical products. The British acquisition will help Namaste develop its medical cannabis distribution platform in the UK. 

READ: Namaste Technologies inks deal with BlueSky Biologicals to distribute CBD products in the UK and Europe

Namaste Technologies has inked a deal with BlueSky Biologicals Inc to distribute their hemp-derived cannabidiol products in the United Kingdom and Europe.

The company also operates an online platform that markets cannabis-related products like vaporizers and smoking accessories in 20 countries and via 30 websites. It also maintains a database of more than 1.5 million customers and has acquired Findify.io and NamasteMD, Canada's first fully integrated patient consultation portal available in the Apple and Google Play stores.

Citron not high on pot stocks

Left's research vehicle, Citron, has aggressively taken aim at Canadian cannabis stocks, which had been on a tear before a pullback in the past 24 hours on a story appearing in Politico claiming marijuana investors and workers risked a lifetime border ban entering the US. Dollinger called those reports "nonsense."

Last week, Citron released a note declaring Canadian cannabis grower Tilray Inc shares (NASDAQ:TLRY) too expensive, tweeting that retail investors have “gone mad.” That was just weeks after making a bullish call on Tilray.

And before that, Left and his team went after Canadian cannabis group Cronos Group Inc (NASDAQ:CRON) in a scathing report, calling it the “most overhyped” of all the cannabis stocks.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

-- Updates with additional details and background information. Christine Corrado and Rene Pastor contributed to this report. -- 

View full N profile View Profile

Related Articles

3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
1534822132_cadoux.jpg
August 21 2018
The company aims to revolutionise the HPA production process, eschewing the laborious bauxite-sourced method.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use